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Introduction
According to the American Heart Association (AHA), ideal cardiovascular health is defined
by the absence of any clinical manifestations of cardiovascular disease (CVD) and the presence of
seven metrics, including not smoking, sufficient physical activity, a healthy diet, a normal body
weight, an optimal total cholesterol level, an optimal blood pressure, and an optimal fasting glucose
in the absence of any drug treatment (Mozaffarian et al., 2015). Clinical manifestations of CVD
include heart failure (HF), heart attack, angina, hemorrhagic or ischemic stroke, and peripheral
vascular disease. It is important to prevent CVD, because in 2011 the total direct and indirect cost
of CVD in the U.S. was approximately $320 billion, which amounted to 15% of the total national
health care expenditures (Mozaffarian et al., 2015). In addition, the AHA predicted that in the year
2030, 43.9% of the U.S. population will have some form of CVD, and that the total direct medical
costs of CVD will increase to $918 billion (Mozaffarian et al., 2015). Furthermore, the number one
cause of death in the U.S. in 2009 was heart disease, with a total of 599, 413 deaths (Center for
Disease Control and Prevention, 2012). Thus, it is important to prevent CVD to prevent unnecessary
medical cost and to decrease morbidity.
HF, one of the clinical manifestations of CVD, is one of the most frequent causes of rehospitalization in the U.S., and it is associated with high rates of morbidity, mortality and cost
(Center for Disease Control and Prevention, 2012). In 2012, an estimated 5.7 million Americans
greater than 20 years old had HF, and by the year 2030, the prevalence of HF will increase by 46%,
where greater than 8 million people over 18 years old will have HF (Mozaffarian et al., 2015).
According to the 2015 AHA statistical update, in 2011 one in nine deaths was caused by HF
(Mozaffarian et al., 2015). The prevalence of HF also increases with age, whereas the lifetime risk
of developing HF for adults 40 years old and greater is one in five. Furthermore, in 2012, the total
8

cost of HF was approximately $30.7 billion, with a projected cost increase of 127% to $69.7 billion
by the year 2030 (Mozaffarian et al., 2015). This means that the cost of HF in the U.S. will increase
by $244 per every adult. Due to the high rates of prevalence, mortality and cost, it is important to
prevent HF, and to treat HF according to current evidence-based therapy.
According to the American College of Cardiology Foundation/American Heart Association
(ACCF/AHA) practice guidelines on the evaluation and management of HF, the standard therapy
in all patients who had a recent or previous history of heart attack or acute coronary syndrome,
regardless of the presence of HF, should be the prescription of angiotensin-converting enzyme
inhibitors (ACEIs) and beta blockers (Yancy et al., 2013). In a comparative effectiveness review
prepared by the Agency for Healthcare Research and Quality (AHRQ), adding ACEIs to the
standard treatment of using beta-blockers can reduce total mortality and hospitalization related to
HF (2010). Though ACEIs clearly benefit patients with HF, the rate of ACEI use is still relatively
low due to its side effects of hypotension, hyperkalemia and cough (Gotsman, Rubovinich, & AzazLivshits, 2008).
Though research showed that ACEIs helped in treating HF, literature showed that in the
outpatient setting, there exist decreased rates of ACEIs prescriptions to HF patients which could be
due to providers’ lack of HF guideline knowledge (Shafazand, Yang, Amore and O’Neal, 2010;
Yancy et al., 2008), uncertainty about risk versus benefits in treating elderly patients since they are
usually underrepresented in randomized controlled trials (Fuat, Hungin and Murphy, 2003; Yancy
et al., 2008), and patient misperceptions to ACEI use (Yancy et al., 2008). Lee et al. (2005) also
found that in HF patients with low-, average-, and high-risk group, ACEIs were prescribed at a rate
of 81%, 73%, and 60% respectively. Furthermore, decreased adherence to guideline recommended
treatment for HF could also be due to improper charting or the failure to account for
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contraindications. Steinman et al. (2011) found that 87% of veterans received ACEIs, but when
chart-documented reasons to not receive ACEIs were excluded, the rates increased to 95%. It is
important to find out the reasons why there exist decreased rates of ACEI use by HF patients
because it could represent missed opportunities for treatment by providers.
This Doctorate of Nursing Practice (DNP) practice inquiry project is made up of three
manuscripts that explore the use of ACEI in the HF population. The first manuscript is a review of
the 2013 HF guideline written by the ACCF/AHA Task Force. This manuscript explored the
guideline in detail and compared it to another HF guideline for ease of applicability. The second
manuscript explored the cost-benefit analysis of using coordinated healthcare delivery systems such
as a patient centered medical home to reduce 30-day hospital readmission for HF exacerbation. The
third manuscript describes a quality improvement project that focused on evaluating the use of
ACEI in a primary care clinic for HF patients. A retrospective chart review with four objectives
was performed in order to: 1) assess for frequency of documentation of an ACEI in current and
active medication lists of patients with HF, 2) assess for documentation of ACEI type, dosages and
dosing frequency in the EMR, 3) assess if an ACEI has been an active medication within a year
prior to the patient encounter, and 4) assess for common documented reasons that HF patients are
not on an ACEI. A focus group was held to discuss: 1) the barriers and facilitators to implementing
ACEI therapy in HF patients in this clinic, 2) the barriers and facilitators to proper documentation
of ACEI use in the clinic, and 3) what can be implemented to facilitate providers’ use of ACEI
therapy in HF patients. Information from the three manuscripts will be used to educate providers
on the necessity of utilizing ACEI in HF patients, and how to increase ACEI use within the practice.
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Analysis of Clinical Practice Guideline Paper on Heart Failure

Heart failure, a manifestation of heart disease, is a chronic condition that causes
progressive and debilitating damage to the body. This disease is one of the most frequent causes
of re-hospitalization in the United States (U.S.), and it is associated with high rates of morbidity,
mortality and cost (Centers for Disease Control and Prevention, 2012). According to the
American Heart Association (2014), in 2010, one out of every three deaths is caused by
cardiovascular disease, with a total mortality of approximately 2.5 million annually in the U.S.
(Go et al., 2014). In 2009, the number one cause of death in the United States was heart disease,
with a total of 599, 413 deaths (Centers for Disease Control and Prevention, 2012). In addition,
in 2010, the estimated direct and indirect medical care cost related to cardiovascular disease was
$315 billion (Go et al., 2014).

Scope and Purpose
Implemented as part of the Patient Protection and Affordable Care Act, starting in the fall
of 2013, hospitals that have patients readmitted within 30 days of discharge due to heart failure
will have reduced Medicare reimbursement, and in 2014, hospitals with high readmission rates
might lose up to 3 percent of their regular Medicare reimbursement (Kaiser Health News, 2013).
With these new rules, it is important for healthcare practitioners to prevent hospital readmission
due to congestive heart failure (CHF). Many forms of treatment for heart failure have been
devised, but these treatments need to be individualized to each patient in accordance with current
guidelines. The three major patient outcomes from the treatment should include relief of
symptoms and improved quality of life, slowing down of cardiac structure abnormalities and
reduced mortality (Velez, Westerfeldt, & Rahko, 2008).
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Since heart failure is a prevalent disease, it is important to treat it appropriately. The
overall objective of the practice guideline written by the American College of Cardiology
Foundation/American Heart Association (ACCF/AHA) Task Force is the improvement of the
quality of care, optimization of patient outcomes, and reducing medical cost for HF patients
(Yancy et al., 2013). In addition, the guideline is created to diagnose and manage the treatment
of most HF patients. However, some patients’ treatment may deviate from the guideline because
that is what is appropriate for the patient’s individual treatment. Thus, the use of this guideline
will depend on the clinician’s judgment and the patient’s current condition. The guideline also
recommends that clinicians should engage patients’ active participation in their medical
treatment through shared decision making. This will help to ensure treatment is tailored to
individual patient’s condition and preference. The purpose of this paper is to analyze the current
HF guideline written by the ACCF/AHA Task Force and discuss how it was developed, when it
should be used and how it compares to another HF guideline in terms of practicality and use.

Stakeholder Involvement
This comprehensive heart failure (HF) guideline is developed in a joint effort by the
ACCF and AHA. The writing committees were made up of experts in the evaluation and care
management of heart failure patients, including physicians and a nurse (Yancy et al., 2013). The
writing committee included general cardiologists, HF and transplant specialists,
electrophysiologists, general internists, physicians with methodological expertise, and members
from ACCF, AHA, the American Academy of Family Physicians, American College of Chest
Physicians, the American College of Physicians, the Heart Rhythm Society, and the International
Society for Heart and Lung Transplantation (Yancy et al., 2013).
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Only one nurse was included in the development of this guideline. The guideline
committee should have included family and adult nurse practitioners. Nurse practitioners take
care of HF patients in their daily practice, and as a result of their clinical experience with these
patients, nurse practitioners could have provided valuable input to the development of the HF
guideline. The writing committee members were diverse enough and included the necessary
groups related to the topic of HF.

Rigor of Development
The authors of the ACCF/AHA Task Force performed an extensive evidence review for
literatures that included studies and reviews up to October of 2011, and some other literature
references through April 2013. The search included publications in English from PubMed,
EMBASE, Cochrane, Agency for Healthcare Research and Quality Reports and other databases
related to HF but not named in the guideline. Some key words used for the searches included:
heart failure, cardiomyopathy, hypertension, dyslipidemia, cardiac catheterization, angiotensinconverting enzyme inhibitors, beta blockers, and cardiac resynchronization therapy (Yancy et al.,
2013). The authors performed a literature review of topics related to the guideline such as
evidence for or against some tests, treatments or procedures for HF, estimates of expected
outcomes, issues of patient preference that may influence treatment choice, and weighted the
strength of evidence for or against a particular test or treatment for HF. However, the guideline
authors did not specify the specific criteria used to select the evidence for the guideline.
For the recommendation formulation, the authors used evidence-based methodologies
developed by the task force, which included the Class of Recommendation and the Level of
Evidence (Yancy et al., 2013). The Class of Recommendation (COR) estimated the size of
treatment effect by considering the risk versus benefits of a treatment or procedure (Yancy et al.,
14

2013). The COR used current evidence to determine whether a treatment or procedure would be
useful or effective and whether it had the potential to cause harm (See Table 1). The Level of
Evidence (LOE) gave an estimate of the level of certainty or precision of the effect of a treatment
(Yancy et al., 2013). The authors reviewed the evidence and ranked it as LOE A, B, or C in order
to support each recommendation in the guideline (See Table 1). For certain evidence where
adequate data could not be obtained, recommendations were made based on expert consensus
and clinical experience, and ranked as LOE C. If possible, any recommendations with LOE C
were supported with historical clinical data and given appropriate references. In addition, if a
recommendation with LOE C only had sparse supporting evidence, a survey of current practice
among clinicians in the writing committee was used as the basis for LOE C with no reference
cited. A summary table for COR and LOE was included in the guideline (See Table 1).
Furthermore, this guideline separated the Class III recommendation to differentiate between
recommendations that had “no benefit” or were associated with “harm” to the patient (Yancy et
al., 2013).
Since this HF guideline addressed patient populations and clinicians in North America,
drugs not available in North America were discussed but not given a COR (Yancy et al., 2013).
Also, studies not performed in North America were reviewed for potential influence on practice
patterns and for any treatment effect and relevance on ACCF/AHA patient population. If the
findings suggested a specific recommendation, it would be included in the guideline with
relevant reference information (Yancy et al., 2013).
The ACCF/AHA guideline for the management of HF gave a clear description of the
relationship between recommendations and the supporting evidence, which can be followed
easily by readers and applied in the clinical setting. The recommendations were separated into
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four parts, each with its own supporting evidence (Yancy et al., 2013). Authors of the guideline
deemed that recommendations with an A level of supporting evidence had results from
randomized clinical trials or meta-analysis, those with a B level of evidence had limited results
from a single randomized trial or nonrandomized studies, and those with a C level of evidence
had results from a limited sample population using consensus of expert opinion, standard of care
or case studies (Yancy et al., 2013). A class I recommendation with an A level of evidence
would have the strongest support and should be applied in the clinical setting. A class IIb
recommendation with a C level of evidence represents results from expert opinions, case studies
or standard of care. This type of recommendation was not well supported with evidence, and was
not encouraged to be used in the clinical setting if not needed. A class III recommendation with
an A level of evidence demonstrated with more than adequate results that the treatment or
procedure could cause harm or provided no benefit for the patient, and should not be performed.
A class III recommendation with a C level of evidence had results from expert opinions, case
studies or standard of care, and the recommendations might be harmful or may not benefit the
patient if performed. The recommendations were appropriate and were placed into categories
according to the correct level of evidence. An example of a Class I with A level of evidence in
the treatment recommendation is that “in patients with a history of myocardial infarction and
reduced ejection fraction (EF), angiotensin converting enzyme inhibitors (ACEIs) or angiotensin
II receptor blockers (ARBs) should be used to prevent HF”; while a harmful class III with C
level of evidence recommendation is that nondihydropyridine calcium channel blockers may be
harmful in patients with low left ventricle EF (Yancy et al, 2013).
Though the recommendations and the supporting evidence were clearly illustrated, the
authors did not show the appropriate steps on how to update the current guideline. The guideline
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only stated that the “ACCF/AHA Task Force were charged with developing, updating and
revisiting practice guidelines for cardiovascular diseases and procedures” (Yancy et al, 2013, pg.
e242). Steps for guideline updates should have been disclosed so that readers could keep up with
the most up-to-date guideline and apply the most appropriate evidence-based practice in the
clinical setting.

Clarity and Presentation
This guideline gives specific and unambiguous recommendations. For example, for the
clinical evaluation of HF patients, a class I recommendation for history and physical examination
would include checking volume status and vital signs at each patient encounter, including serial
weight, estimation of the jugular venous pressure and a check for the presence of peripheral
edema (Yancy et al., 2013). This recommendation had a B level of evidence, so according to the
authors, this recommendation should be performed because patients would benefit from it.
Another example would be for the ambulatory setting, if a patient presented with dyspnea,
authors recommended checking for biomarkers including BNP or N-terminal pro-B-type
natriuretic peptide (NT-proBNP) to support clinical decision in regards to HF diagnosis,
especially if there was uncertainty in the diagnosis. This recommendation had an A level of
evidence, which according to the authors should be done because it would benefit the patient.
This guideline showed specific and unambiguous recommendations, which makes it easy to
adapt in the clinical setting.
This guideline also gives different options for management of HF. An example would be
for stage B HF with reduced ejection fraction (EF), in a class I recommendation, patients with a
recent or previous history of myocardial infarction (MI) should be prescribed angiotensinconverting enzyme inhibitors (ACEI) or an angiotensin II receptor blocker (ARB) if unable to
17

tolerate ACEI, in order to prevent symptomatic HF and to reduce mortality (Yancy et al., 2013).
This recommendation had an A level of evidence. In addition, the authors also recommended the
use of beta blockers for stage B HF with reduced EF in patients with a recent or previous history
of MI to help reduce mortality (Yancy et al., 2013). This recommendation had a B level of
evidence. This guideline clearly stated that ACEI should be prescribed for stage B HF with
reduced EF, but if patients could not tolerate ACEI, ARB could be used as a substitute for it. In
addition, beta blockers could be used if ACEI or ARB could not be tolerated but with a lower
supporting level of evidence. Thus, the guideline suggests different management options for
stage B HF with reduced EF, and allows clinicians some degree of freedom for patient treatment.
Lastly, in this current guideline, the key recommendations were written in boldface, so
readers can easily recognize them. The use of boldface separates out the key recommendations
from other explanations, so readers can quickly and easily locate the recommendations for easy
application to the clinical setting. Also, the authors created tables for a summary of key
recommendations for HF treatment. The tables are easy to follow, with clear explanations which
reiterate key recommendations to readers. The guideline is user friendly and can easily be
followed from one recommendation to the next.

Application
This current HF guideline is comprehensive in that it includes many different
management options for HF and even quality improvement metrics for HF. However, some of
the treatment options could not be applied easily by all clinicians due to treatment complexities
and cost. An example could be the cardiac resynchronization therapy (CRT). CRT, also called
biventricular pacing, is a specialized pacemaker therapy where it paces the heart through
multiple sites (Yancy et al, 2013). CRT is more commonly used for left bundle branch block to
18

promote synchrony between the right and left ventricles, and thus, improving the pumping
efficiency of the heart (Shea, & Sweeney, 2003). Though this treatment can be performed by
most electro physiologists, it should only be performed by clinicians in centers with the expertise
and tools for it for better patient outcome. Since this treatment may incur a high cost, which
should be covered by insurance if meeting the guideline implementation criteria, only treatment
facilities with adequate financial capabilities offer this treatment (Yancy et al., 2013). In
addition, continuous patient follow-up with cardiologist is essential for successful treatment. If
the patient is not consistent in going to follow-up visits, this non-adherence may reduce the
potential positive effect of the CRT treatment. The high cost and complexities of this treatment
may serve as a barrier to implementation of this treatment by many healthcare organizations. In
addition, some of the other treatments such as inotropic support for inpatient hospitalization
should only be performed by centers that have a specialized cardiac unit for maximum
utilization. A facility needs to have adequate staffing and expertise to open a specialized cardiac
unit. Training staff and hiring the necessary experts to run the facility would require a lot of
capital. Thus, not all recommendations in the guideline could be applied by every clinician due
to the cost and complexities of the treatments recommended.
This guideline does not address some of the organizational barriers in treatment
application and treatment cost implications. The lack of discussion on cost and barrier
implications may hinder treatment application by clinicians who had the ability to use these
treatments. Thus, the ACCF/AHA Task Force would need to discuss organizational barriers and
cost implications in future guideline updates in order to allow clinicians greater understanding of
the different treatment complexities and costs. A guideline with a clear discussion of treatment
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options, complexities, and cost could reduce uncertainty and allow for easy application by
clinicians.

Theoretical Framework
In order to guide the application of this guideline to practice, clinicians must be educated
continuously about the guideline. The concept of learning through continuous education could be
explained well by Albert Bandura’s social learning theory. Bandura (1971) proposed that direct
reinforcement could not account for all learning types, and that people could also learn through
observing others, known as observational learning.
In addition, Bandura (1971) believed that observational learning is guided by four
interrelated processes: attention, retention, reproduction and reinforcement or motivational. In
order to learn a new behavior, a person needs to pay attention, observe the behavior, retain the
newly learned behavior in the memory bank, and draw out the stored behavior in the future.
After learning the new behavior, it is important to reproduce the behavior and practice it so as to
improve the behavior. Lastly, positive reinforcement makes a person perform the new behavior
while negative reinforcement decreases a person’s motivation to perform the newly learned
behavior (Bandura, 1971).
Clinicians could use this theory to guide application of the HF guideline. Those in charge
would need to draw their colleagues’ attention to the problems related to HF. They would need
to find out why clinicians are not using the HF guideline and educate them about its importance.
Positive reinforcements such as better patient outcomes and increased patient satisfaction with
receiving the appropriate treatment will encourage clinicians to use the guideline more often.
Continuous education about guideline applications would be the easiest and best way to ensure
that clinicians understood the importance of using evidence-based therapy in treating HF
20

patients. Reminders about using the guideline and evidence-based therapies could be placed in
the electronic health records or pamphlets could be placed in the exam rooms. The continuous
presence of reminders will increase clinicians’ awareness, and hopefully increase the chances of
clinicians using the HF guideline to treat HF patients.

Editorial Independence
The American College of Cardiology Foundation and the American Heart Association
(ACCF/AHA) sponsored the development of the guideline. The ACCF/AHA selected the expert
authors to be on the guideline committee in order to create the current HF guideline. The
ACCF/AHA explicitly stated that they did not influence the guideline’s development, and the
authors examined evidence, reviewed it, and updated the guideline independently.
In addition, the ACCF/AHA task force made sure that no conflict of interest could arise
due to author’s relationship with the health-care industry. The ACCF/AHA Task Force made it a
necessity for the authors to disclose any health care relationship, from current ones to 12 months
before the writing of the guideline (Yancy et al., 2013). In addition, the task force created a new
policy that stated that the committee chair and a minimum of 50% of the writing committee had
to have no relevant relationship with the health care industry (Yancy et al., 2013). Lastly, the
authors disclosed any relationship they had with any industry in appendices one and two.

Recommendation
Another guideline for HF was developed by the Heart Failure Society of America
(HFSA) in 2010. This treatment guideline used three grades, A, B, and C to assess the strength of
evidence, similar to the ACCF/AHA HF treatment guideline. But for the strength of
recommendation, the HFSA used “totality of evidence,” which categorized recommendations
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into several categories using phrases. The first recommendation, “is recommended,” meant the
recommendation should be part of routine care with minimal exceptions, “should be considered”
meant the recommendation should be applied to the majority of patients with exceptions for
some individuals, “may be considered” meant that the therapy should be given on an
individualized basis, and lastly, “is not recommended” meant the therapy should not be used
(Lindenfeld et al., 2010). The strength of recommendation for the HFSA guideline is not as
comprehensive as the recommendations in the ACCF/AHA guideline. In addition, the
ACCF/AHA simplified the level of evidence and strength of recommendation in a table, but this
is not the case in the HFSA guideline. The lack of comprehensive recommendation and
simplicity in the HFSA guideline reduced ease of application in the clinical setting.
In the treatment recommendations, the guideline developed by the ACCF/AHA clearly
differentiated the treatment options in bold font for simplicity but the HFSA did not differentiate
the treatment options. In the HFSA guideline, it is more difficult to differentiate the treatment
options from the rest of the treatment explanations. However, the HFSA provided a summary
table for medication treatment and dosages for HF patients with reduced EF. This allows
clinicians to apply the treatment easily in the clinical setting. The ACCF/AHA guideline did not
give dosages for medication treatment, perhaps assuming that clinicians would know what
dosages to start patients on. This lack of guidance might make it difficult for newly graduated
clinicians to understand how to apply the guideline in the busy clinical setting.
Lastly, the ACCF/AHA guideline is easier to understand since the guideline compared
each treatment and showed evidence on which treatments should be applied and which should
not. The HFSA guideline did not compare treatments but explained each treatment in detail. The
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detailed explanations were useful, but comparison of treatments should be added to help
clinicians to understand which treatment performed better and should be given to patients.
The ACCF/AHA guideline seems preferable because the guideline was created in a
simplistic way, easy for readers to understand and apply in the clinical setting. The tables in the
guideline were clear and provided further detail. The guideline was not so long that it made it
difficult for readers to read and understand. The guideline was created with the right amount of
information so clinicians could self-study it and apply it in their daily practice.
Lastly, this guideline is preferable because it was created for general use in HF treatment.
Any family nurse practitioner could read the guideline and apply the information in their daily
practice. However, some of the more specialized treatment recommendations such as the CRT
therapy or the heart transplant could not be performed by the nurse practitioner. These
specialized therapies were written for cardiologists working in the hospital setting. It is important
to practice evidence-based therapy in all clinical settings, especially to treat HF patients, because
the healthcare cost of letting this condition go untreated could be high. Good evidence-based
treatment could decrease the cost burden for this disease and benefit many people. Any nurse
practitioner should read and understand this guideline, and use it in their daily clinical practice to
guide the treatment of HF patients.
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A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical
questions addressed in the guidelines do not lend themselves to clinical trials. Although randomized trials are unavailable, there
may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of
diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of
comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

Table 1. Applying Classification of Recommendation and Level of Evidence (Yancy et al.,
2013).
Reprinted with permission: Circulation. 2013; 128: e240-e327. 2012 American Heart
Association, Inc.
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Cost-benefit Analysis of a Patient Centered Medical Home for Reducing
30-day Hospital Readmission for Heart Failure Exacerbation

Heart failure (HF) is one of the most frequent causes of re-hospitalization in the United
States (U.S.), and it is associated with high cost and high rates of morbidity and mortality. In
2009, the total hospitalization costs for heart failure in persons aged 65 years or older was
estimated at $20.1 billion, and the average hospitalization cost per patient increased from $7,000
in 1990s to $18, 086 currently (Wang, Zhang, Ayala, Walla, & Fang, 2010). According to the
American Heart Association (AHA) 2014 statistical update, in 2010, one out of every three
deaths was caused by cardiovascular disease, with a total mortality of 2,468,435 (Go et al.,
2014). In 2013, the number one cause of death in the United States was heart disease, with a total
of 611,105 deaths (Centers for Disease Control and Prevention, 2014). In addition, in 2010 the
estimated direct and indirect medical care cost related to cardiovascular disease was $315 billion
(Go et al., 2014). Implemented as part of the Affordable Care Act, starting in the fall of 2013,
hospitals will have reduced Medicare reimbursement if patients are readmitted for the diagnosis
of heart failure (HF) within 30 days of discharge. In 2014, hospitals with high HF readmission
rates could lose up to 3 percent of their regular Medicare reimbursement (Medicare Payment
Advisory Commission, MedPAC, 2013). It is essential to prevent hospital readmission due to HF
so hospitals will not lose part of their reimbursement and to improve the quality of life for
patients with this chronic disease.

Background
In the U.S., preventable hospital readmissions can be costly to patients, hospitals and
insurance companies. Among the Medicare population, an average of 20% of the patients were
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readmitted within 30 days, and these readmissions cost Medicare an estimated 12 billion dollars
each year (Thorpe, & Cascio, 2011). Hospital readmissions could signify poor quality of care, as
well as poor coordination of care between primary care providers and acute care providers.
Following the enactment of the 2010 Affordable Care Act, the Center for Medicaid Services
(CMS) implemented the hospital readmissions reduction program (HRRP) in October of 2012
(MedPAC, 2013). HRRP worked by reducing payments to hospitals that had excess preventable
readmissions during the previous three years. In fiscal year 2013, the penalty was capped at one
percent of inpatient base operating payments. This cap increased to two percent in 2014 and to
three percent in 2015. The penalty will stay at three percent after 2015 (MedPAC, 2013). With
the implementation of the HRRP, the goal is that hospitals will reduce readmission rates by
improving their quality of care, coordinating discharges with primary care providers, and
involving multidisciplinary members in the patients’ care both before and after discharge by
using the patient-centered medical home (PCMH) model. The PCMH model is a
multidisciplinary care system that seeks to provide comprehensive healthcare to patients and to
ensure that the patient and family members are involved as core members of the team (Agency
for Healthcare Research and Quality (AHRQ), 2012). The purpose of this cost-benefit analysis is
to reduce the 30-day hospital readmission rate due to HF by employing a patient centered
medical home (PCMH) model.

Benefits of the PCMH Model
The PCMH model was a part of the 2010 Patient Protection and Affordable Care Act.
PCMH was developed in an effort to reduce the rising cost of healthcare, increase patient
involvement in their care, result in better coordination between acute care providers and primary
care providers, and improve quality of care (Berryman, Palmer, Kohl, & Parham, 2013). The
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PCMH can be used as an effective framework for tailoring interventions for HF patients by
producing measurable improvements in outcomes, such as reducing the rate of avoidable
readmissions (Somers, & Cunningham, 2011).
The PCMH model is a coordinated care delivery system that provides comprehensive
primary and acute care services such as administering health risk assessments, providing
preventive care services, and chronic condition management. The PCMH uses a team of
physician-led healthcare providers for care provision. The team includes nurse practitioners,
physician assistants, registered nurses, pharmacists, nutritionists, therapists and social workers,
with the patient at the center of the care (Christensen et al., 2013). With this care model, the
primary care provider will coordinate all the healthcare services that a patient needs, such as
primary care services, specialty care, hospital care, home healthcare, and other supports (Rich,
Lipson, Libersky, & Parchman, 2012). For example, if the patient needs home healthcare
services, the primary care provider will coordinate this; and, if the patient requires rehabilitation
services after a hospital stay, the primary care provider will coordinate this, and ensure that the
patient is followed in order to prevent unnecessary readmissions (Rich, Lipson, Libersky, &
Parchman, 2012). This concept of PCMH enables continuity of care, which helps to develop
better patient-provider relationships, thus improving patient outcomes and reducing healthcare
costs.
Christensen et al. (2013) found the use of the PCMH model reduced hospital medical
care costs by 11% for patients with chronic conditions, as compared to seven percent lower for
those without a chronic condition. This shows the use of PCMH in treating patients with chronic
conditions such as HF can have significant benefits, especially in terms of reducing costs to the
healthcare system. One study found that this type of system could save as much as $4,845 per
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patient for the healthcare system after accounting for the cost of implementation (Osei-Anto,
Audet, Berman, & Jencks, 2010). This is significant considering a recent study estimated the
mean inpatient cost for HF patients is $9,923 per patient, and the 30-day readmission rate for
these HF patients is 22.9% (AHRQ, 2012). Inpatient hospital costs attributed to such
readmissions can be up to $2,084 per patient per day (Casteel, 2012).
Reid et al. (2010) did a two-group, quasi-experimental before-and-after evaluation study
over two years to gauge a prototype PCMH’s impact on cost, quality and experience at a clinic in
Seattle, Washington. 6,187 adult patients were surveyed at baseline, and at 12 months and 24
months post PCMH formation, measuring patient experiences in care coordination, care access,
goal setting, quality of doctor-patient interactions, and patient involvement. The study found that
the PCMH model helped to improve patients’ experience and quality of care, reduced provider
burnout, reduced emergency visits by 29 percent and hospitalization by six percent, and provided
an estimated healthcare savings of $10.30 per patient per month after 21 months of program use.
However, the major limitation of this study is that it is based on the result of one clinic. In order
for the result to be generalizable, future studies should include a number of other clinics and a
diverse patient population. Though the study only used results from one clinic, this prototype
clinic showed that the PCMH care model can substantially reduce healthcare costs by reducing
the healthcare expenditures, improving primary care delivery, and improving patient outcomes.
Therefore, the PCMH model can be used to coordinate all the care for HF patients with a goal of
reducing hospital readmission rates, reducing medical care costs and helping to improve
healthcare quality for this population.
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Figure 1. Benefit model of PCMH
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PCMH Design
The purpose of this paper is to recommend a PCMH program design that can help to
coordinate the care of HF patients after hospital discharge. According to Berryman, Palmer, Kohl
and Parham (2013, p. 166), the basic idea for a PCMH should include the following:
•

Presence of a relationship between the patient and the medical provider,

•

Presence of a provider who will take charge of all the care of the patient including
arrangements for specialty care,

•

Continuous care that is managed by the same provider to guarantee care
coordination and collaboration,

•

Transparent and fair payments with quality and safety as the key aspect of the
system.

The PCMH program will employ a primary care provider who will coordinate the care post
discharge from the hospital and acquire all the needed information from the acute care provider.
The primary care provider will then coordinate the patient’s care with the other interdisciplinary
team members. The patient and family members will be involved throughout the process. Other
interdisciplinary team members will include the nurse practitioner, heart failure registered nurse,
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pharmacist, dietician, and social worker. The nurse practitioners will help the primary care
provider monitor the patient’s condition post hospital discharge, and help to reiterate heart failure
teaching each time the patient is seen. A heart failure registered nurse will follow up with the
patient by calling him/her at home to answer any questions the patient may have. The pharmacist
will monitor the patient’s lab values and adjust heart failure medications as needed. The dietician
will work closely with the patient to create a plan for healthy living such as eating healthfully
and exercising. Lastly, the social worker will work with the patient to provide materials or
equipment needed for the patient’s home care.
Figure 2. PCMH design
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Implementation Process
In order to implement a PCMH program to treat HF patients in an existing hospitalowned clinic, stakeholders will need to be invited to participate in the program. Before creating a
budget plan, it is important to make sure that there are enough providers to handle the PCMH
patient load, if not, more providers will need to be hired. The number of providers needed will
depend on the number of patients seen. At the same time, staff such as heart failure registered
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nurses, pharmacists, dieticians, and social workers will need to be hired if none were present in
the existing clinic. The number of staff will also depend on the patient load. Clinic policies and
standard operating procedures such as clinical practices, clinical documentation, client privacy
rights and responsibilities, staff job descriptions, risk management, and admitting, discharging
and referral procedures will need to be developed before the PCMH can be started. Lastly,
billing rates, gross margins, clinic expenses, and setting aside at least three months of operating
capital to pay bills will need to be calculated and created.
After getting the PCMH set up, providers will need to work closely with insurance
companies to make sure that the program can be reimbursed for the appropriate patient care.
Since the PCMH is created from an existing clinic, where the clinic is owned by a hospital,
patients will be referred to the clinic by the hospital. However, providers may still need to recruit
patients, especially if providers see those patients in the hospital as inpatients.

Organizational Buy-in
Since starting a PCMH program requires financial funding and stakeholders, a key point
of the cost-benefit calculation of this innovation is identifying the cost of implementation. A
recent study estimated that the average cost for converting a practice into a PCMH is $517,000
per full-time equivalent (FTE) provider (Zuckerman et al., 2009). Thus it is important to find
stakeholders who are willing to invest a large sum of money and explain to them how this
investment will be beneficial in the long run. In this case, the stakeholders in an existing
hospital-owned clinic will include hospital administrators and the organization that owns the
hospital. The use of the attention, interest, desire and action (AIDA) business marketing strategy
will help gain the stakeholders’ attention (SANS Institute, 2001). Attention means providing
information that will capture the attention of stakeholders and addressing any misconceptions.
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Interest stands for providing examples of successful PCMH programs at similar facilities to the
stakeholders in order to gain their interest. Desire stands for increasing the desire of stakeholders
to value an innovation that may result in improved patient care and satisfaction, and improved
efficiency. Lastly, action stands for motivating stakeholders to participate in the required
activities.
It is also important to engage stakeholders by allowing them the opportunities for
feedback and voicing of concerns. Consequently, it is also important to offer incentives for
providers who produce measurable improved outcomes (such as a decrease in readmission rates)
by giving bonuses for achieving the target of reduced readmission rates after five years of
evaluation. Providing incentives for stakeholders will improve the chance of organizational buyin, thus obtaining funding to start the PCMH program.

Cost-Benefit Analysis
The PCMH program requires much funding to start from the beginning. However, over
time the program will help heart failure patients by reducing 30-day hospital readmission rates,
reducing medical care costs, improving patient outcomes and providing high quality patient care
(Christensen et al., 2013; Osei-Anto, Audet, Berman, & Jencks, 2010). Thus, to get stakeholders’
buy-in, a hypothetical cost-benefit analysis (CBA) was created to show the positive aspects of a
PCMH program (see figure 3 and 4). 100 HF patients were used for ease of CBA calculations.
Figure 3. Positive and negative aspect of a PCMH program
Costs of readmission due to heart failure
Benefits of using PCMH to reduce
exacerbation
readmission rates due to heart failure
Direct costs:
• Provider, physician
• Nursing
• Medications
• Room/hospital charge

Direct costs averted:
• Decrease penalty from CMS
• Decrease hospitalization cost
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• Equipment
• Procedures
Productivity losses:
• Loss of time from work
• Loss of income
• Loss of reimbursement from CMS to
hospitals

Productivity losses averted:
• Work absenteeism costs averted
• Deaths prevented, so able to preserve
earnings from work
• Averted the cost of reduced work
effectiveness

Figure 4. Cost-Benefit Analysis (CBA) of a PCMH Program
Cost to implement a PCMH per provider
$ 517,000
(Zuckerman, 2009)
Average readmission rate for HF in US in
2012 (CMS, 2014)

24.1%

Mean cost per stay for HF readmission in
U.S. in 2012 (AHRQ, 2012)

$13,634

Out of 100 patients, 24.1% readmission rate

100 x 24.1% = 24.1 = 24 patient readmitted to
hospital due to HF

Total expected readmission cost

24 x $13,634 = $327,216

Reduce readmission rate by 20%, only 80%
out of 24 readmitted to hospital

24 x 80% = 19.2 = 19

Readmission cost after preventing 20% from
being readmitted

19 x $13,634 = $259,046

Cost saved per year by reducing readmission
by 20%

$327,216 - $259,046 = $68,170

Money saved by decreasing readmission in 5
years

$68,170 x 5 = $340,850

Total money spent in first year to start a
PCMH and reducing 20% HF readmission

$68,170 - $517,000 = $-448,830

Years needed before reaching break-even
point of $517,000

$517,000/$68,170 = 7.6 = 8 years

The benefit of using PCMH to manage care for HF patients post initial discharge from
the hospital in the first year after implementation, may help save an estimated $68,170 per year
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per 100 HF patients seen in the PCMH, with a 20% reduction in readmission rate. In the first
year, the PCMH will not save money. Instead, money will have to be spent up front to fund the
start of the PCMH, which amounts to $448,830. In addition, if the PCMH operated for five
years, the money saved by decreasing readmission rates would be $340,850. According to the
CBA calculation, if healthcare cost remains the same, which is improbable, it will take
approximately 8 years for the PCMH to hit the break-even point and to potentially recoup more
than $517,000 in healthcare cost by preventing hospital readmissions.
The CBA calculations showed that it is difficult to implement a PCMH, even from an
existing hospital-affiliated clinic because it takes a lot of up-front capital and it can take years to
begin to see any profit or benefit of money saved in this case. Though it takes a while before one
can see possible benefit from implementing a PCMH, this type of coordinated healthcare
delivery system is beneficial in coordinating care and decreasing healthcare cost, especially for
chronic diseases such as HF (Christensen et al., 2013).

Evaluating the Effectiveness of the PCMH
Just like other medical programs, it is important to evaluate the effectiveness of the
PCMH program. The effectiveness evaluation will give providers some input as to whether the
patients are benefiting from the program, and whether medical costs decreased or increased after
the use of a PCMH program to manage HF. In order to evaluate the effectiveness of the PCMH
model, there should be a decrease in hospital readmission rate by 20%, reach the breakeven point
of $517,000 and acquire savings from PCMH implementation in eight years. Savings in this case
means a decrease in the cost of treating HF patients by way of money saved from preventing
hospital readmission. A program effectiveness survey for staff members should be done in 1 year
in order to improve the quality of care in the PCMH.
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In order to measure a decrease in hospital readmission rate by 20% in eight years,
hospital readmission data will need to be obtained from patients, acute care providers and
hospitals. It is also important to measure HF compliance outcomes such as dietary compliance
and medication management. This will determine if the closer contact between patients and
providers could create better patient outcomes. Lastly, an estimate in reduction of healthcare
costs related to reduce readmission rates could be calculated. If the healthcare costs to treat
chronic diseases such as HF decreased, it means that the PCMH worked to help reduce
readmission rates and healthcare costs.
In addition to measuring if the cost of treating HF patients in eight years decreased,
calculations will be made to find out how much money is saved by preventing hospital
readmissions. In order to calculate the money saved, it is important to assume that the clinic is
owned and operated by a hospital. If the clinic is not affiliated to any hospital, it will be hard for
the clinic to save money by preventing hospital readmissions. This is because the calculated
money saved is not profit that the clinic will receive but money saved by preventing patients
from being sick. In addition, money saved by preventing readmission takes a while to
accumulate. Thus the time frame selected was eight years. This time frame will allow the cost
saved to be significant in terms of preventing hospital readmission.
Lastly, it is important to develop a survey for staff to participate so the program’s
effectiveness could be measured through the eyes of the staffs. With the result of the survey, the
program coordinator could develop a quality improvement plan to improve the program’s
effectiveness for better patient care in the future.
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Limitations
One of the limitations of the CBA is that the calculation is based on an estimate of 100
HF patients per full-time equivalent primary care provider (PCP). It is difficult to obtain a rough
estimate of the average number of HF patients seen per PCP because every clinic does not see
the same number and type of patients. Most PCPs do not handle a big number of HF patients in a
year. Thus the calculation is based on the best estimate available.
In addition, for a small clinic that is not affiliated to a hospital, it will take them longer to
save money on the return on investment because the money is not profit that the clinic will
receive. It is money that the clinic will save and will not spend by preventing the patient from
being sick. Thus, it will be more worth it if the PCMH clinic is affiliated to a hospital because
both the hospital and PCMH clinic will benefit by preventing HF patients from being readmitted
within 30-days of hospital discharge.
Nonetheless, PCMH has the potential to benefit other chronic conditions such as diabetes
mellitus and hypertension (CMS, 2014; Rich, Lipson, Libersky, & Parchman, 2012). It can help
to decrease the cost of those associated care, thus potentially could lead to an earlier savings
related to the PCMH. But those chronic conditions were not included for the purpose of this
CBA since the focus here was on HF.
Furthermore, creating a PCMH requires a lot of up-front capital for the initial start-up,
and it will take years before the stakeholders can begin to see some profit or benefit from the
PCMH. This may contribute as a difficulty for small, private clinics convert their current practice
into a PCMH. Lastly, if the PCMH has less patients, then it will take more time for return on
investments to exceed the cost of turning the clinic into a PCMH. With 100 patients, it takes at
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least eight years before the clinic hit the breakeven point of $517,000 and recoup that money by
preventing healthcare cost related to hospital readmissions.

Conclusion
Though the concept of PCMH is relatively new, this idea can help to improve the medical
field, especially for those patients with chronic diseases such as HF. PCMH can provide a more
patient-centric care by proactively addressing patients’ needs (Christensen et al., 2013). Since
most studies on PCMH measures patient satisfaction and patient outcomes, future studies could
include healthcare members’ feelings and satisfaction on using this PCMH model, and how the
PCMH model helps to reduce/increase the workload of the healthcare members. In addition,
future studies could also include a survey on the healthcare members’ willingness to change their
current way of patient care into the PCMH model. By including the thoughts of the healthcare
members, it will help to decrease team members’ alienation, decrease the feeling of being
overwhelmed and decrease team members’ resistance to the use of a new concept like PCMH. In
the long run, this PCMH concept can help to provide a high quality care, reduce 30-day
readmission rate for HF, reduce medical care cost, better patient outcome and improve patient
satisfaction with the medical team.
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Abstract

Background: ACEI has been shown to help decrease mortality, morbidity, rate of rehospitalization, and to improve symptoms of heart failure (HF). However, the rate of ACEI use
for HF patients remain low despite the recommendations made by the ACCF/AHA Task Force in
the current 2013 HF guideline. It is important to increase the use of ACEI because of its positive
effect on the outcome of HF. In addition, improper charting could skew the number of patients
who are actually taking ACEI, making it less than it actually it. Thus, providers should be on the
forefront of encouraging ACEI use, especially for HF patients.

Purpose: The purpose of this study is to evaluate if heart failure patients, aged 18 and over, in a
primary care clinic receive ACEI therapy as recommended by the current 2013 HF guideline
written by the American College Cardiology Foundation/American Heart Association
(ACCF/AHA) Task Force.

Methods: This is a retrospective chart review study that will assess for documentation of ACEI
therapy in heart failure patients. Unique medical records meeting the inclusion criteria will be
reviewed for: the number of patient encounters within the past year, visit day of the week, age,
ethnicity, gender, type of health insurance (Medicare, Medi-Cal, private insurance, and
uninsured), select vital signs (systolic blood pressure, diastolic blood pressure, and heart rate),
ACEI on current active medication list, generic name of ACEI, dose of ACEI, and frequency of
ACEI per day. If the patient does not have an ACEI on the current, active medication list, the
chart will be reviewed over the year prior to the patient encounter for documentation of an ACEI
on active medication list within the past year, an angiotensin-receptor blocker (ARB) on the
patient medication list, a hydralazine/isosorbide combination on the patient medication list,
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allergy to ACEI, cough due to ACEI, hypotension due to ACEI, angioedema due to ACEI, and
documentation of other reason for not being on ACEI. Additionally, a focus group will be held
after results are analyzed. The focus group will have result dissemination and questions for
discussion with providers.

Results: 63 charts were reviewed, and the results showed that only 20.6% of patients were
currently taking ACEI for HF. The most common cause of not taking ACEI was due to allergies.
Out of the 50 charts that did not have ACEI on the current medication list, 42% did not have any
type of documentation on why the patient was not on an ACEI. The focus group found that
barriers to utilization of ACEI for HF patients included improper or incomplete documentation by
the medical assistants (MAs), medication list not up to date because the MAs did not take the time
to go through the list with patients, and patient’s lack of knowledge on the disease process and
treatment of HF.

Conclusion: Based on the results of the study, proper medication reconciliation by the patient and
MAs could help to improve documentation and improve the number of actual ACEI use.
Decreasing patient load could help improve quality of patient and increase patient satisfaction.
This will increase patient involvement in the treatment plan, thus increasing rate of adherence to
ACEI. Lastly, continuous guideline education will encourage provider to use evidence-based
therapies to treat HF.
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Evaluation of Primary Care Providers’ Utilization of ACEI therapy in Heart Failure Patients

Introduction
Heart failure (HF), a clinical manifestation of cardiovascular disease, is a chronic
condition that causes progressive and debilitating damage to the body. In 2012, an estimated 5.7
million Americans greater than 20 years old had HF, and by the year 2030, the prevalence of HF
will increase by 46% and greater than 8 million adults will have HF (Mozaffarian et al., 2015).
According to the AHA (2015) statistical update, in 2011 one in nine deaths was caused by HF,
with a total death toll of 58,309 during that year. The prevalence of HF also increases with age,
and the lifetime risk of developing HF for adults 40 years old and greater is one in five. In
addition, there were approximately 1.8 million outpatient visits with a primary diagnosis of HF
in 2010. Furthermore, in 2012, the total cost of HF was approximately $30.7 billion, with a
projected cost increase of 127% to $69.7 billion by the year 2030. This means that the cost of HF
will increase by $244 per every adult with HF in the U.S (Mozaffarian et al., 2015). This disease
is also one of the most frequent causes of re-hospitalization in the U.S. with 870,000 new cases
diagnosed yearly through 2011, and it is associated with high rates of morbidity, mortality and
cost (Centers for Disease Control and Prevention, 2012). Due to the high rates of prevalence,
mortality and cost, it is important to prevent HF, and to treat it according to current evidencebased guidelines.
According to the American College of Cardiology/American Heart Association
(ACC/AHA) practice guideline on the evaluation and management of heart failure, the standard
therapy in all patients who had a recent or previous history of heart attack or acute coronary
syndrome, regardless of the presence of HF, will be the prescription of angiotensin-converting
enzyme inhibitors (ACEIs) and beta blockers (Yancy et al., 2013). Though ACEIs clearly benefit
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patients with HF, the rate of ACEI use in the U.S. is still relatively low due to its side effects of
hypotension, hyperkalemia and cough (Gotsman, Rubovinich, & Azaz-Livshits, 2008).

Background
ACEIs have been shown to decrease mortality, morbidity, and re-hospitalization in HF
patients. Studies of the Left Ventricular Dysfunction (SOLVD) investigators (1991); Keyhan,
Chen, and Pilote (2007); and Hess, Preblick, Hill, Plauschinat, and Yaskin (2009) found that
ACEIs helped to reduce the rate of re-hospitalization, decrease mortality, and improve survival
from congestive HF if a patient was compliant with the medication. Keyhan, Chen, and Pilote
(2007) noted that ACEIs decreased mortality in women by 20 percent and by 29 percent in men.
In the SOLVD study, enalapril, an ACEI, was used in patients with low ejection fraction to see if
it would reduce the rate of mortality, myocardial infarction and re-hospitalization (SOLVD,
1991). This study with 2569 participants, which lasted for 41 months, showed that with use of
enalapril there were decreases in total mortality, in the number of deaths due to cardiovascular
disease, and in the rate of hospitalization due to worsening HF. In addition, investigators in the
Prevention of Hypertension With the Angiotensin-Converting Enzyme Inhibitors Ramipril in
Patients with High-Normal Blood Pressure (PHARAO) study found that over a period of 3 years,
treatment with ramipril, an ACEI, significantly reduced progression to hypertension
manifestation by 34.4% as compared with the control group (Luders et al., 2008). Hence, the use
of ACEI can also slow down the progression of other comorbidities of heart failure, such as
hypertension.
The 2013 ACC/AHA practice guideline on HF also recommends the use of hydralazine
and isosorbide dinitrate (H/I) combination in patients who cannot tolerate ACEIs or ARBs due to
drug intolerance, hypotension or renal insufficiency (Yancy et al., 2013). The (H/I) combination
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has been shown to improve quality of life and hemodynamic output and reduce recurrent
hospitalizations due to heart failure (Golwala et al., 2013; Anand, Win, Rector, Cohn, & Taylor,
2014; Taylor et al., 2007; Mullens et al., 2009; Cohn et al., 1986).
However, ACEIs are not without adverse effects. Studies have shown that providers were
hesitant to prescribe ACEIs to patients due to adverse effects such as hyperkalemia, increased
serum creatinine levels and angioedema. Gotsman, Rubovinich, and Azaz-Livshits (2008);
Beltrami, Zanichelli, Zingale, Vacchini, and Carugo (2011); and Miller, Oliveria, Berlowitz,
Fincke, and Stang (2012), found that the most common reasons provider discontinued ACEI
were increased serum potassium levels and elevated serum creatinine levels. In the follow-up
visit, hypotension and coughing were the main reasons where patients discontinued ACEI use
(Gotsman, Rubovinich, and Azaz-Livshits, 2008). Furthermore, patients may still contract
angioedema, even after discontinuation of an ACEI; and ACEIs needed to be used cautiously in
certain race groups such as African Americans, because the rate of angioedema in that
population is four times higher as compared to Caucasians (Miller, Oliveria, Berlowitz, Fincke,
and Stang, 2012). Moreover, the rate of angioedema was higher by 50% in the female population
than in the male population, and the overall ACEI associated angioedema is 2.7 per 1000 people
and years of ACE use.
Though research shows that ACEIs should be used to treat HF, literature shows that in the
outpatient setting, there are suboptimal rates of ACEIs prescriptions for HF patients. This could
be due to decreased guideline familiarity (Shafazand, Yang, Amore, & O’Neal, 2010; Yancy et
al., 2008), uncertainty about risks versus benefits in treating elderly patients since they are usually
underrepresented in randomized controlled trials (Fuat, Hungin, & Murphy, 2003; Yancy et al.,
2008), or patient misperceptions of ACEI use (Calvin et al., 2012). Lee et al. (2005) found that for
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HF patients in the low-, average-, and high-risk groups, ACEIs were prescribed at a rate of 81%,
73%, and 60% respectively. Patients in the highest risk group for death due to left ventricular
ejection fractions (LVEFs) of less than 40% and other co-morbidities had the lowest rates of
ACEI prescription. In the IMPROVE HF study, investigators found that among the eligible older,
higher-risk HF patients, only 68% received ACEI or ARB (Yancy et al., 2008). In addition, the
analysis of the Acute Decompensated Heart Failure National Registry (ADHERE) for adherence
to HF quality-of-care indicators in U.S. hospitals found that only 72% of patients with
documented left ventricular systolic dysfunction were prescribed ACEI on discharged from the
hospitals (Fonarow et al., 2005).
In the Heart Failure Adherence and Retention Trial (HART) study, investigators studied
the non-adherence pattern of physicians to prescribing evidence-based therapy according to the
2005 ACC/AHA HF guideline, and the non-adherence pattern of patients to taking prescribed
medications (Calvin, et al., 2012). Physician non-adherence would be failure to prescribe ACEI,
ARB or beta-blocker in the absence of contraindications, or did prescribed medications in the
presence of known contraindications. The investigators found that 37% of physicians were nonadherent to evidence-based therapy for HF, while 63% were adherent; 10.8% of patients who
should be on an ACEI or ARB were not prescribed it, and 74.1% of patients who had
contraindications to ACEI or ARB were prescribed it (Calvin et al., 2012). This study found that
non-adherence to evidence-based guideline therapy for HF could be due to patient reasons such as
depression, cost, cultural factors, effects on sexual function, poor health literacy and medication
adverse effects.
Lastly, decreased adherence to guideline-recommended treatment for HF could also be
due to lack of, as well as improper documentation or the failure to document for
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contraindications. Steinman et al. (2011) found that 87% of veterans were prescribed either an
ACEI or an ARB; but when specific reasons such as contraindications to ACEIs or ARBs were
documented in the chart the rates of ACE or ARB prescribing according to recommended
guidelines increased to 95%. Improper documentation masked the actual number of ACEI use,
making it seemed like less patients were prescribed the proper guideline recommended treatment.
In addition, Atwater et al. (2012) found that only 44% of HF patients with an EF of less than or
equal to 45% received guideline recommended treatment. After accounting for medical
contraindications, the number went up to 72%, with an adherence to ACEI guideline
recommendations for HF of 95%. Thus, proper documentation is important because it will give
providers a view of patients’ current therapies and any additional therapies that is needed.
It is important to find out the reasons why providers are not following the recommended
HF guideline in the use of ACEIs for HF treatment because it could represent missed
opportunities in treating patients. Continued education in current clinical practice guidelines may
be needed in helping providers and patients adhere to current clinical practice guidelines and help
to reduce some of the uncertainties regarding the use of ACEIs in heart failure treatment (Calvin
et al., 2012).

Purpose and Aims
The purpose of this study was to evaluate if HF patients aged 18 and over, in a primary
care clinic, receive ACEI therapy as recommended by the 2013 HF guideline written by the
American College Cardiology Foundation/American Heart Association (ACCF/AHA) Task
Force.
The objectives of the study were to assess for frequency of documentation of an ACEI in
current and active medication lists of patients with HF; assess for documentation of ACEI type,
46

dosages and dosing frequency in the electronic medical record (EMR); assess if an ACEI has been
an active medication within a year prior to the patient encounter; and, assess for common
documented reasons that HF patients are not on an ACEI.

Methods
This was a retrospective chart review study. Charts with International Classification of
Diseases (ICD), 9 th revision codes for HF of 428.0, 428.1, 428.20, 428.21, 428.22, 428.23,
428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43 and 428.9 were included in the
study. A software program called AdvanceMD was used to identify medical records meeting the
study criteria. This software allowed the PI to insert the required ICD-9 code and the study time
frame and pull up all the patient encounters for the specific ICD-9 code(s).
A discussion session guide (figure 5.) was created to direct a provider discussion session
after the retrospective chart review portion of the study. The discussion session disseminated deidentified study results to the provider and discussed barriers and facilitators to proper
documentation of ACEI, barriers and facilitators to implementing ACEI therapy in the clinic, and
possible facilitators to providers’ utilization of ACEI therapy in HF patients.

Human Subject and Research Approval Procedures
Permission to conduct the retrospective chart review was obtained from the University of
Kentucky’s IRB. A waiver of informed consent was obtained for the retrospective chart review
since this portion of the study used existing patient records, and no direct contact between the
investigator and subjects would take place. Approval to obtain provider informed consent as
normal volunteers was also obtained from the University of Kentucky’s IRB. The owner of the
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clinic gave permission for the study to be completed there, so a letter of agreement for data
collection was obtained from the study clinic.

Sample
Only charts with an encounter date between January 1, 2014 and December 31, 2014,
with documentation in the EMR were analyzed. If a patient visited the clinic multiple times
during this period, only the most recent visit that fell within the period of January 1, 2014 to
December 31, 2014, was included in the study. Inclusion criteria were 1) adults, both male and
female, 2) all ethnicities, 3) age greater than or equal to 18 years, 4) a diagnosis of HF, 5) a
patient encounter at the clinic between January 1, 2014 and December 31, 2014, 6) patients seen
by consenting providers, and 7) charts with ICD-9 codes of 428.0, 428.1, 428.20, 428.21, 428.22,
428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43 and 428.9. Exclusion
criteria were 1) no diagnosis of HF, 2) age less than18 years, 3) a patient encounter not
documented in the EMR, 4) a patient encounter that was not between January 1, 2014 and
December 31, 2014, and 5) patient encounters where the PI had documented. Sixty-three medical
records met the inclusion criteria.
The sample for the discussion group included all providers who were practicing in the
clinic from the period of January 1, 2014 to December 31, 2014. Only those providers that signed
the provider informed consent as a normal volunteer were included in the discussion session. If
the provider did work at the clinic during the period of January 1, 2014 to December 31, 2014, but
no longer worked at the clinic at the time of the study, attempts were made to contact and to
include the providers in the discussion session. Exclusion criteria were 1) providers that did not
work in the clinic between January 1, 2014 and December 31, 2014, and 2) providers that did not
sign the informed consent. One provider met the discussion session inclusion criteria.
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Design
All charts meeting the inclusion criteria were included in the study. Unique medical
records meeting the inclusion criteria were reviewed using a chart audit tool developed by the PI
(see figure 6.). The chart audit tool was reviewed by a content expert. Using the chart audit tool,
identified charts were reviewed for the number of patient encounters within the past year, visit
day of the week, age, ethnicity, gender, type of health insurance (Medicare, Medi-Cal, private
insurance, or uninsured), select vital signs (systolic blood pressure, diastolic blood pressure, and
heart rate), ACEI on current active medication list, generic name of ACEI, dose of ACEI, and
frequency of ACEI per day. If the patient did not have an ACEI on the current, active medication
list, the chart was reviewed over the year prior to the patient encounter for documentation of an
ACEI on active medication list within the past year, an angiotensin-receptor blocker (ARB) on
the patient medication list, a hydralazine/isosorbide combination on the patient medication list,
allergy to ACEI, cough due to ACEI, hypotension due to ACEI, angioedema due to ACEI, and
documentation of other reasons for not being on ACEI.
After the completion of the study a discussion session was held with a consenting
provider and de-identified results were disseminated to the provider at the clinic. Prior to
discussion session, discussion objectives were created in order to facilitate the discussion with
providers (see figure 5.) During the discussion session, the primary investigator (PI) reviewed
the 2013 HF guideline written by the ACCF/AHA Task Force and the retrospective chart review
results with the provider and discussed the provider’s thoughts on possible barriers and
facilitators to utilizing ACEI therapy for HF patients in the clinic, barriers and facilitators to
documentation of ACEI use, and ways to decrease barriers to ACEI utilization by providers in
the clinic.
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Setting
This retrospective record review took place in an internal medicine clinic in a suburban
town in Southern California.

Data collection
For data collection, a master code sheet and a chart audit tool were created. The master
code sheet contained the patient’s chart number, and each chart number were assigned a study
number. Only the study number and data collected were recorded in the chart audit tool. The
master code sheet and chart audit tool were always kept separate. The master code sheet was
kept in a locked file cabinet, in a locked office where it could only be accessed by the PI. The
chart audit tool was kept on the PI’s password protected computer.
By entering the HF ICD-9 codes of 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.30,
428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43 and 428.9, along with clinic visit date
range between January 1, 2014 to December 31, 2014 into the AdvanceMD software, 63 charts
were found that met the inclusion criteria stated above.

Data analysis
Results from the retrospective chart review were analyzed using the IBM Statistical
Package for the Social Sciences (SPSS) v. 22 software. Descriptive statistics such as frequency,
percentage, range, mean and standard deviation were used to analyze age, gender, ethnicity,
insurance type, number of clinic encounters, systolic blood pressure, diastolic blood pressure,
heart rate, current ACEI therapy, type of ACEI, dose and frequency of ACEI, current ARB
therapy, current hydralazine/Isosorbide therapy, ACEI allergy, ACEI-associated cough,
hypotension, angioedema, other reason documented for not being on ACEI, and if a reason was
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documented for not being on ACEI. Correlations were analyzed using 2-sample T-test and
Pearson/Fisher’s Exact Test, with statistically significant results set at p < 0.05.

Reliability and Validity
Consistency of data collection was maintained by having the primary investigator (PI) as
the only person collecting the data for the retrospective chart review and conducting the provider
focus group interview. To test for content validity, a clinical expert on the topic of HF reviewed
the chart audit tool and determined the tool appropriate to collect the data needed to meet the
study objectives.

Results
Sample characteristics
63 charts met the inclusion criteria for the retrospective chart review. From the 63 charts,
40 (63.5%) of the patients were female and 23 (36.5%) were male, with a mean age of 69 (range
= 38-93, SD = 12.0). Most of the patients fall in the age group between 71 to 80 years old, none
were between 18 to 30 years old, and two were between 91 to 100 years old (See Table 2).
Patients’ ethnicities included 65.1% White, 25.4% Hispanic, 6.3% Asian, 1.6% Pacific
Islander/Native Hawaiian, and 1.6% other. Among the 63 charts, 36 (57.1%) had private
insurance, while 14 (22.2%) had both Medicare and private insurance. Twelve (19.1%) had only
Medicare, 1 (1.6%) had both Medicare and Medi-Cal, and none were uninsured (Table 2).

Clinical characteristics
Comparison of patient clinical characteristics showed the mean systolic blood pressure
was 121.1 mmHg (range = 96-150, SD = 10.1), the mean diastolic blood pressure was 74.7
mmHg (range = 58-92, SD = 7.7), and the mean heart rate was 73.4 (range = 50-100, SD = 9.4)
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(See Table 3). The systolic blood pressure, diastolic blood pressure and heart rate included
patients who had ACEI in the current, active medication list and who did not have ACEI in the
current, active medication list. With heart failure as one of the working diagnoses, most patients
visited the clinic more than once per year, with a mode number of encounter of 8 (mode = 8;
range = 2-28) in the past year. Lastly, of the 63 charts reviewed, 50 (79.4%) did not have an
ACEI listed as one of the current medication therapies, as compared to 13 (20.6%) that did
(Table 3). Furthermore, 24 (38.1%) charts out of the 63 charts reviewed did not have any ACEI,
ARB, Hydralazine/Isosorbide therapy, or any reasons documented for not being on ACEI (Table
4).
Among the 13 charts that listed ACEI as a current therapy, seven (53.8%) were taking
lisinopril, five (38.5%) were taking ramipril, and one (7.7%) was taking benazepril. In addition,
the median cumulative dose of ACEI was 5 mg (range = 2.5-40.0; Table 5).
For those patients who were not taking ACEI at the time of the study (n = 50), 21 (42%)
of them were on ARB therapy, and three (6%) of them were on hydralazine/isosorbide therapy
(Table 6). Six (12%) had an allergy to ACEI, two (4%) had ACEI associated cough, and none of
the 50 charts listed hypotension or angioedema as a reason for not taking ACEI. Four (8%) other
charts documented other reasons, not including allergy, ACEI associated cough, hypotension or
angioedema, for not having ACEI on the current active medication list. Out of 50 charts, 26
(52%) documented a reason for not being on an ACEI while 24 (48%) did not have
documentation for not being on an ACEI for HF treatment (Table 6).
In comparing those patients who were taking/not taking ACEI, there was no significant
difference in the age of those patients who were taking (M = 69.0, SD = 9.6) or not taking (M =
69.3, SD = 12.9; p = 0.93, two-tailed) ACEI at the time of the study. More females than males
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were taking ACEI for HF (n = 13; 8 [61.5%] vs. 5 [38.5%]). At the same time, more females
than males were also not currently taking ACEI for HF treatment (n = 50; 32 [64%] vs. 18
[36%]). However, the proportion of males who were currently taking ACEI was not significantly
different from the proportion of females who were currently taking ACEI (Figure 7). There
appeared to be no association between whether the patients were taking ACEI at the time of
study and gender, χ2 (1, n = 63) = 0.00, p = >.99, phi = 0.02 (Table 7).
In the ethnicity category (n = 13), eight (61.5%) White and five (38.5%) Hispanic
patients had ACEI on the current, active medication list; and (n = 50) 33 (66%) White, 11 (22%)
Hispanic and six (12%) other ethnicity did not have ACEI on the current, active medication list
(Figure 8). The proportion of whites who were currently taking ACEI were not significantly
different from the proportion of Hispanics who were currently taking ACEI. There appeared to
be no significant association between ethnicity and whether the patients were taking ACEI for
HF at the time of the chart review, χ2 (2, n = 63) = 2.70, p = 0.26, phi = 0.21 (Table 7).
When comparing the type of insurance a patient had with taking ACEI at the time of the
chart review, with n = 13, nine (69.2%) had private insurance, three (23.1%) had both Medicare
and private insurance, one (7.7%) had only Medicare, and none had combined Medicare/MediCal or no insurance at all. For those that were not taking ACEI at the time of the study, with n =
59, 27 (54%) had private insurance, 11 (22%) had both Medicare and private insurance, 11
(22%) had only Medicare, one (2%) had both Medicare and Medi-Cal, and none was uninsured
(Figure 9). The proportion of patients that had different insurance, such as Medicare, private,
Medicare/Medi-Cal and Medicare/private, and were currently taking ACEI were not significantly
different from the proportion that did not took ACEI at the time of the chart review. There
appeared to be no significant association between the type of insurance and whether the patients

53

were taking ACEI for HF at the time of the study, χ2 (3, n = 63) = 1.79, p = 0.62, phi = 0.17
(Table 7).
In addition, there was no significant difference in the systolic blood pressure of those
patients who were currently taking (M = 120.2, SD = 10.1) or not taking (M = 121.5, SD = 10.2;
p = 0.683, two-tailed) ACEI. Moreover, there also was no significant difference in the diastolic
blood pressure of those patients who were currently taking (M = 73.7, SD = 6.4) or not taking (M
= 74.9, SD = 8.1; p = 0.609, two-tailed) ACEI. Lastly, there was no significant difference in the
heart rate of those patients who were currently taking (M = 72.0, SD = 7.0) or not taking (M =
73.8, SD = 9.9; p = 0.536, two-tailed) ACEI (Table 7).

Provider Discussion Session
Only one provider, an internal medicine physician, participated in the provider discussion
session. The discussion session objectives and questions (see figure 5) were used to facilitate the
provider discussion session. De-identified results were disseminated and the 2013 HF guideline
written by the ACCF/AHA Task Force was discussed with the provider. In addition, three
questions were discussed (per the discussion guide). First, the provider was asked what were
possible barriers and facilitators to implementing ACEI therapy in HF patients at the clinic. The
provider stated one barrier was patient preference, for example, patients were unwilling to
continue with ACEI therapy due to side effects such as cough and light-headedness not due to
hypotension. Another identified barrier was medication lists that were not up-to-date because a
medication list reconciliation was not performed at the beginning of the patient encounter.
Lastly, provider preference was identified as playing a role in implementing ACEI therapy in HF
patients at the clinic. This provider preferred to use Toprol Succinate ER or XL, particularly for
diastolic HF patients, instead of ACEI. The provider also suggested that medication cost played a
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part in as both a facilitator and barrier to ACEI implementation in the clinic’s HF patient
population. The provider stated that patients who had health maintenance organization (HMO)
insurance were often concerned with medications cost, including the costs of ACEIs. Since
ACEIs were available for a low cost at some pharmacies, this low cost medication appealed to
patients and the low cost facilitated its use in the HF population at the clinic.
For the second question, the provider was asked to discuss barriers and facilitators to
proper documentation of ACEI use in the clinic. According to the provider, often, medical
assistants (MAs) did not obtain or reconcile the patient’s current medication list. The provider
reported often writing an encounter’s note on paper and then the note was entered into the EMR
by the MAs at a later time. This contributed to inaccurate, missed, or incomplete documentation.
The provider reported seeing 50 to 60 patients per day and this patient volume was a barrier to
proper medication reconciliation and documentation in the current medication list. As for
facilitators to proper ACEI documentation, the clinic had a medication reconciliation sheet that
patients could complete while waiting to be seen. This medication reconciliation sheet that was
in place during the study period, provided the provider and the MAs a tool to facilitate updating
the patient’s current medication list. The provider reported improvement in medication
reconciliation using the medication reconciliation sheet when properly utilized. In addition, the
new EMR software the clinic began using in December of 2013, made it easier for the provider
and clinic staff to edit or enter medications in the medication list.
The last question asked the provider what could be implemented in order to facilitate
providers’ use of ACEI therapy in HF patients in this practice. The provider suggested that in
order to raise awareness of the ACCF/AHA 2013 HF guideline, among the physicians, nurse
practitioners and physician assistants in the clinic, a meeting to discuss the HF guideline should
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be held at least biannually. The meeting could be used to discuss any questions about the HF
guideline and HF treatment options.
The provider concluded that the discussion session helped the provider to understand
some of the documentation problems that the clinic experienced. The provider discussion session
could help the clinic to improve its documentation process and increase the quality of HF patient
care in the future.

Discussion
The use of ACEI has been shown to decrease mortality rates, cost and re-hospitalization
of patients due to worsening of HF (The SOLVD investigators, 1991; Hess, Preblick, Hill,
Plauschinat, & Yaskin, 2009; and Chen et al., 2011). ACEI have also been shown to improve
functional capabilities and to decrease symptoms of HF patients (Luders et al., 2008). Therefore,
it is essential that primary care providers treat HF with the appropriate medication, dose and
frequency of ACEI, according to the 2013 ACCF/AHA HF guideline. However, the rate of ACEI
use is still relatively low due to its side effects of hypotension, hyperkalemia and cough
(Gotsman, Rubovinich, & Azaz-Livshits, 2008). The results of the study in this clinic were no
different. From the retrospective chart review, only 20.6% of the patients had ACEI in the
current medication list for HF treatment. This low number is disconcerting because the study
showed that less than 1 out of 4 patients took ACEI for treatment of HF. Since ACEI has been
shown to help decrease mortality, re-hospitalization and costs of HF, its usage should be higher.
Though the rate of ACEI use was low, 42% of the patients that were not on an ACEI had
ARB on the current, active medication list, and 6% had hydralazine/isosorbide therapy. This
showed that even if patients were not able to use ACEI due to some reasons, ARB or
hydralazine/isosorbide therapy was used, which followed the recommendations of the
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ACCF/AHA HF guideline (Yancy et al., 2013). In addition, according to the chart review, 12%
of the patients were allergic to ACEI, and 4% had ACEI-associated cough. None of the charts
listed hypotension or angioedema as reasons not to take ACEI. The study results were similar to
the literature review, in that the main reason for discontinuing ACEI was cough. Though the
patients did not complain of angioedema or hypotension, the provider would still need to monitor
the patients’ blood pressure and checked for symptoms of angioedema each time the patients
come in for a visit.
Twenty-four (38.1%) of 63 charts reviewed did not indicate the presence of ACEI, ARB,
or hydralazine/isosorbide combination on the current medication list, did not indicate reasons
why no ACEI was prescribed such as allergies, cough, hypotension or angioedema, and did not
indicate other reasons for not being on an ACEI. These patients represented missed opportunities
for use of ACEI as based on the HF guideline. Since the provider did indicated that
documentation of medication reconciliation was an issue, it might be possible that similar to
Atwater et al. (2012), with proper documentation, the number of ACEI utilization might
increase. If the number of ACEI utilization did not increase, proper documentation of why
patients were not on an ACEI would allow providers to manage HF appropriately according to
the next therapy specified in the guideline.
The chart review also showed that 48% of the HF patients who were not on ACI therapy
had no documented reasons for why the patients were not on ACEI. This is lower than what
other literature has found, and could be either due to providers not following guideline
(Shafazand, Yang, Amore, & O’Neal, 2010; Yancy et al., 2008; Calvin et al., 2012) or due to
documentation issues (Steinman et al., 2011; Atwater et al., 2012).
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Furthermore, in the discussion session, the provider ascertained that the biggest barrier
the clinic has to following the HF guideline is incomplete documentation. Since the provider sees
many patients each day, the MAs are not able to complete the documentation during the office
visits. As a result, the provider writes the encounter note including diagnosis, assessment and
treatment plan on a paper, and the MA then transcribes the provider’s note a later time according
to what was written on the paper. This transfer of data has the potential for errors.
The study found no association between age, gender, ethnicity, and insurance type and
whether the patients were currently taking ACEI for HF. Nevertheless, the study sample did not
have any patients without insurance. The ACEI treatment of HF patients should not differ based
on age, gender, ethnicity or insurance. However, the study results differ from the current
literature, which indicate that age-related differences do play a part in the use of evidence-based
therapies, such as ACEI, ARBs, and beta-blockers, to manage HF (Forman et al., 2009; Fonarow
et al., 2009). This difference could be due to the small sample size of the study, or even
inaccurate charting.
Lastly, there was no significant difference between the systolic blood pressure, diastolic
blood pressure and heart rate of the patients who were currently taking ACEI and those who
were not. The non-significant difference in study result could be due to the small sample size.
This study result is different than what is found in the current literature, where ACEI has been
found to improve the functional capabilities of HF patients, and helps to prevent the progression
of hypertension, thus decreasing the future development of HF (The SOLVD investigators, 1991;
Keyhan, Chen, & Pilote, 2007; Luders et al., 2008).
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Limitations
One of the limitations of this study was the small number of charts available for the
review. The small sample makes it difficult to generalize the study to the general HF population.
Another limitation of the study was that other medications used to lower blood pressure
such as diuretics or calcium-channel blockers were not included. These medications could have
played a part in reducing patients’ blood pressure, thus making it seemed like ACEI did not play
a part in decreasing patients’ blood pressure (Da Silva, 2010; James et al., 2014; Keyhan, Chen,
& Pilote, 2007; Luders et al., 2008; The SOLVD investigators, 1991). However, this study was
specific for ACEI, thus other medications for blood pressure were not included.
In addition, upon performing the retrospective chart review, no documentation was found
to indicate who started the ACEI, ARB or hydralazine/isosorbide therapy for HF treatment. The
provider also did not remember which patients had the ACEI started in the clinic. Thus, it was
not possible to figure out if the clinic provider or the specialist started the HF treatment. As a
result, it was impossible to deduce which provider used evidence-based therapy to treat patients.
Another major limitation was the number of providers available for the discussion
session. Only 1 provider participated. Thus, the results were only the perspective of one clinic
provider. The answers could contain biased viewpoints from the one provider. Results could
have been different if there were other providers such as nurse practitioners or physician
assistants.
Lastly, another limitation was that the private insurance was not divided into PPO or
HMO groups. According to the provider, all the HMO patients were referred to a specialist for
HF management, while the PPO patients were not referred out. The difference in treatment
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modalities between the HMO and PPO patients could produce a difference in the presence of
ACEI in the current, active medication list.

Implications for Practice
It is important that primary care providers treat HF according to the evidence-based
guidelines for treatment. Providers’ lack of understanding of practice guidelines, improper or
incomplete charting and patient refusal to use ACEI could be reasons why current ACEI use for
HF patients in the clinic is only 20.6%.
Providers’ lack of practice guideline comprehension could be due to decreased guideline
familiarity (Fonarow et al., 2008; Shafazand, Yang, Amore, & O’Neal, 2010; Yancy et al.,
2008). Providers need to not only understand guidelines, but also implement guidelines based on
evidence from research rather than using personal preferences to guide practice (Shafazand,
Yang, Amore, & O’Neal, 2010). In order to encourage increased evidence-based practice
guideline use, continuing education is a type of educational strategy that can benefit many
primary care providers (PCP). Continuing education can help to provide PCPs with current
evidence-based guideline recommended treatment for HF, translate knowledge from current
research that benefits HF patients, and increases providers’ awareness and perceptions to HF
guideline (Parnicka, Wizner, Fedyk-Lukasik, Windak & Grodzicki, 2013). By being
knowledgeable about HF practice guideline, providers can improve the quality of care for HF
patients.
In addition, having a copy of the guideline uploaded into the computer so it could be
pulled out at any time electronically for ease of access helps to increase providers’ utilization of
the guideline (Rattay, Ramakrishnan, Atkinson, Gilson, & Drayton, 2009). Since this clinic does
not have a clinical decision support software as part of their EMR, adding a software that can
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show decision support for every patients with HF in the EMR can also help providers to decide
which treatment, according to the evidence-based practice guideline, should be chosen for the
patient. By having an EMR with clinical decision support tools for HF, it allows providers to
manage HF while maintaining patient safety and patient satisfaction at the same time (Vries et
al., 2013; Schnipper et al., 2008). However, overdependence on the clinical decision support tool
may not be conducive because the clinical decision support tool could make an inaccurate
recommendation since technology is not always accurate (Vries et al., 2013; Harrington,
Kennerly, & Johnson, 2011). Additionally, technology could never replace a person’s thought
process. Thus having an EMR with a clinical decision support tool is good but overreliance is not
encouraged.
Another method that can help to improve documentation is periodic chart audit for
compliance. Chart audits can give insight on overall clinic compliance as well as individual
provider’s compliance, while helping to improve patient safety and helping to reduce potential
avoidable harm (AHRQ, 2012). Depending on resources available at any primary care clinic,
chart audits can be performed retrospectively, either electronically or manually, using minimal
staff provided they are trained in the audit process. Chart audit results can help to identify areas
of low compliance, such as medication reconciliation and incomplete documentation, and allow
providers to tailor improvement strategies according to the audit results (AHRQ, 2012).
Furthermore, hiring more PCPs can help to lighten the patient load per provider in any
clinic. In recent years, chronic diseases had become widespread and poorly controlled, and time
constraints due to heavy patient load had been attributed as one of the reasons for this concern
(Ostbye et al., 2005; Yarnall et al., 2003). Additionally, heavy patient load could also contribute
to clinician burnout, increase medical errors and decrease the quality of patient care (Willard-
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Grace, et al., 2014). Thus, increasing the number of clinicians working in the clinic is one of the
ways that can help to decrease patient load. With a lighter patient load and the presence of other
providers, hopefully, these will increase teamwork, increase the exchange of information
between providers and increase the frequent use of clinical guidelines for evidence-based
therapies and treatments (Altschuler, Margolius, Bodenheimer, & Grumbach, 2012; Ostbye et
al., 2005; Willard-Grace, et al., 2014).
Moreover, if a provider’s patient load decreases, providers will have time to document
during each patient’s visit in the EMR. Incomplete documentation can occur if the
documentation is not completed daily. The presence of many incomplete charts could be a
precursor to future documentation errors (Steinman et al., 2011; and Atwater et al., 2012). If
providers document on the EMR and complete it during every patient’s visit, it will help to
decrease documentation errors or incomplete charting (Steinman et al., 2011; Atwater et al.,
2012). In addition, extra training in EMR documentation can help to decrease the rates of
documentation errors and improve visit documentation by provider (Haugen, 2012; Keehbauch
et al., 2012). These will help to improve clinic performance by increasing the quality of patient
care and increasing patient satisfaction.
Lastly, increasing patient education about the side effects of ACEI could help to decrease
the rate of patient refusal. In this study, 12% of the patient had an allergy to ACEI, while 4% had
an ACEI-induced cough. None of the study participants had hypotension or angioedema due to
ACEI. If patients were educated that taking ACEI could cause ACEI-associated cough and that
it should eventually decrease as time passes by, patients may be more inclined to stay on ACEI
even with the cough (Gotsman, Rubovinich, & Azaz-Livshits, 2008). Thus, it is important to
spend time during each patient’s visit to educate patients about the disease diagnosis and
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treatment plan. Repetitive education will have better retention, patients will understand the
reasons why they need treatments for HF, and they will be more involved in the treatment plan
(Gotsman, Rubovinich, & Azaz-Livshits, 2008). Getting patients involved in the treatment team
will ensure that patients are more apt to adhere to treatment plans.

Conclusion
Providers must be knowledgeable about the HF guideline and prescribe the appropriate
treatment for HF, including ACEI when indicated. Patients with HF depend on primary care
providers as gatekeepers and for disease treatment and management. Rates of ACEI use in those
with HF can be low due to improper documentation or patients’/providers’ preferences. It will
require effort to increase the rate of ACEI use through continued education and support for both
providers and HF patients. Future studies can explore correlation between proper medication
documentation with provider-patient ratio, rate of HF guideline use in the presence of clinical
decision support tool in the EMR, and the effect of providing continuing education on the rate of
guideline utilization. ACEI must be used appropriately in treating HF because it can help to
reduce mortality, morbidity and re-hospitalization, and therefore can help to reduce the rising
cost of healthcare (Yancy et al., 2013).
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Figure 5.
Discussion session objectives
1. Review appropriate utilization of ACEI therapy in heart failure patients as recommended
by the 2013 HF guideline written by the American College Cardiology
Foundation/American Heart Association (ACCF/AHA) Task Force.
2. Review de-identified study results with clinic providers.
3. Assess for provider’s thoughts on possible barriers and facilitators to utilizing ACEI
therapy for heart failure patients in the clinic.
4. Assess for barriers and facilitators to documentation of ACEI use.
5. Assess for ways to decrease barriers to ACEI utilization by providers in the clinic.

Discussion Questions
1. What are barriers and facilitators to implementing ACEI therapy in heart failure
patients in this clinic?
2. What are barriers and facilitators to proper documentation of ACEI use in the clinic?
3. What can be implemented to facilitate providers’ utilization of ACEI therapy in heart
failure patients?
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Figure 6.
Chart Audit Data Table for Medical Record Review
Type of Insurance
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Figure 7.

Figure 8.
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Figure 9.
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Table 2. Demographic and clinical characteristics of the study sample (N = 63)
Mean (SD); Range
Demographic characteristics
Age

69.0 (12.0); 38-93

Demographic characteristics

n (%)

Age Group
18-30

0

31-40

1 (1.6%)

41-50

3 (4.8%)

51-60

14 (22.2%)

61-70

12 (19.0%)

71-80

24 (38.1%)

81-90

7 (11.1%)

91-100

2 (3.2%)

Gender
Male

23 (36.5%)

Female

40 (63.5%)

Ethnicity
White

41 (65.1%)

Hispanic

16 (25.4%)

Asian

4 (6.3%)

Pacific Islander/Native Hawaiian

1 (1.6%)

Other

1 (1.6%)

Insurance
Medicare

12 (19.1%)

Uninsured

0 (0%)

Private

36 (57.1%)

Medicare and Medi-Cal

1 (1.6%)

Medicare and Private

14 (22.2%)
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Table 3. Clinical Characteristics of patients in the clinic (N=63)
Clinical characteristics

Mode; Range

Number of encounters

8; 2-28

Clinical Characteristics

Mean (SD); Range

Systolic blood pressure

121.2 (10.1); 96-150

Diastolic blood pressure

74.7 (7.7); 58-92

Heart rate

73.4 (9.4); 50-100

Table 4. Characteristic of ACEI Therapy Utilization (N=63)
ACEI Therapy

n (%)

Current ACEI therapy
Yes

13 (20.6%)

No

50 (79.4%)

Not on ACEI, ARB, Hydralazine/Isosorbide

24 (38.1%)

therapy, no documented reasons for not
being on ACEI

Table 5. Clinical characteristics of patients on ACEI (n = 13)
Median; range or n (%)
Type of ACEI
Benazepril

1 (7.7%)

Lisinopril

7 (53.8%)

Ramipril.

5 (38.5%)

Cumulative dose

5; 2.5-40.0
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Table 6. Reasons why patients are not on ACEI (n = 50)
Mean (SD); range or n (%)
Current ARB therapy
Yes

21 (42%)

No

29 (58%)

Current Hydralazine/Isosorbide therapy
Yes

3 (6%)

No

47 (94%)

ACEI Allergy
Yes

6 (12%)

No

44 (88%)

ACEI Associated Cough
Yes

2 (4%)

No

48 (96%)

Hypotension
No

50 (100%)

Yes

0

Angioedema
No

50 (100%)

Yes

0

Other reason documented
Yes

4 (8%)

No

46 (92%)

Reason documented for not being on ACEI
Yes

26 (52.0%)

No

24 (48.0%)
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Table 7. Comparison between patients who are currently taking/not taking ACEI
ACEI
p

Age

Yes (n = 13)

No (n = 50)

Mean (SD) or n (%)

Mean (SD) or n (%)

69.0 (9.6)

69.3 (12.9)

Gender

.93
>.99

Male

5 (38.5%)

18 (36.0%)

Female

8 (61.5%)

32 (64.0%)

Ethnicity

.26

White

8 (61.5%)

33 (66.0%)

Hispanic

5 (38.5%)

11 (22.0%)

Other

0 (0%)

6 (12.0%)

Medicare

1 (7.7%)

11 (22.0%)

Private

9 (69.2%)

27 (54.0%)

Uninsured

0 (0%)

0 (0%)

Medicare and Medi-Cal

0 (0%)

1 (2.0%)

Medicare and Private

3 (23.1%)

11 (22.0%)

Systolic Blood Pressure

120.2 (10.1)

121.5 (10.2)

0.68

Diastolic Blood Pressure

73.7 (6.4)

74.9 (8.1)

0.61

Heart Rate

72.0 (7.0)

73.8 (9.9)

0.54

Insurance

71

.66
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Conclusion
Heart failure (HF) is a preventable disease that has a high treatment cost. According to
the ACCF/AHA practice guidelines on the evaluation and management of HF, the standard
therapy in all patients who had a recent myocardial infarction (MI) or a history of MI, regardless
of HF status, will be the use of ACEI or beta-blockers. Angiotensin II Receptor Blockers (ARBs)
can be used as an ACEI substitute if the patient has an allergic reaction to ACEI (Yancy et al.,
2013).
Though ACEI has been shown to decrease mortality rates, cost and re-hospitalization of
HF patients (The SOLVD investigators, 1991; Hess, Preblick, Hill, Plauschinat, & Yaskin, 2009;
and Chen et al., 2011), the rate of ACEI use is still relatively low due to its side effects of
hypotension, hyperkalemia and cough (Gotsman, Rubovinich, & Azaz-Livshits, 2008). This
study showed that less than 1 out of 4 patients took ACEI for treatment of HF. Of the 63 charts
reviewed, 38.1% did not indicate the presence of ACEI, ARB, or hydralazine/isosorbide
combination on the current medication list; did not indicate allergy, cough, or hypotension as the
reason why no ACEI was prescribed; and did not indicate other reasons for not being on an
ACEI. These patients represented missed opportunities for use of ACEI based on the HF
guideline.
In order to improve the quality of patient care and patient satisfaction, it is important that
primary care providers (PCPs) utilized evidence-based practice guideline for disease treatment.
Providers’ lack of knowledge of the practice guidelines, incomplete documentation and patient
preference could be reasons why current ACEI use is low.
In order to increase providers’ understanding and implementation of practice guidelines,
continuing education is an educational strategy that can benefit many PCPs. Continuing
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education can help to provide PCPs with current evidence-based guideline recommended
treatment for HF and assist them in translating knowledge from current HF research into practice
(Parnicka, Wizner, Fedyk-Lukasik, Windak & Grodzicki, 2013).
Having a copy of the guideline available electronically for ease of access may help to
increase providers’ utilization of the guideline (Rattay, Ramakrishnan, Atkinson, Gilson, &
Drayton, 2009). Furthermore, using clinical decision support tools as part of the EMR, can help
providers to decide which treatment, according to evidence-based practice guidelines, should be
chosen for a patient. Clinical decision support tools allow providers to manage disease treatment
while maintaining patient safety and patient satisfaction (Vries et al., 2013; Schnipper et al.,
2008).
In order to reduce incomplete documentation, extra training in EMR documentation can
help to decrease the rates of documentation errors and improve visit documentation by providers
(Haugen, 2012; Keehbauch et al., 2012). The presence of many incomplete charts could be a
precursor to future documentation errors (Steinman et al., 2011; and Atwater et al., 2012). If
providers document using the EMR and complete documentation during every patient’s visit, it
will help to decrease documentation errors or incomplete documentation (Steinman et al., 2011;
Atwater et al., 2012). If heavy patient load contributes to documentation issues, hiring more
providers may help to decrease the patient load, thus allowing providers more time to chart and
to provide safe patient care (Willard-Grace, et al., 2014).
Lastly, increasing patient education about the side effects of ACEI could help to decrease
the rate of patient refusal. It is important to spend time during each patient’s visit to educate
patients about disease diagnosis and treatment plan. Repetitive education increases retention;
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patients will understand the reasons why they need treatments for HF and will be more involved
in the treatment plan (Gotsman, Rubovinich, and Azaz-Livshits, 2008).
Failure to follow the current guideline for HF treatment could lead to increased mortality
and morbidity for those with HF. The reasons why healthcare providers are not following
evidence-based HF guidelines must be uncovered and explored to ensure opportunities for
treating HF patients are not missed. Future studies could focus on the frequency with which
providers utilize practice guideline for disease treatment and possible interventions to increase
providers’ ACEI use in HF patients. Utilizing ACEI, in those with HF, is essential to decrease
rates of mortality, morbidity, and re-hospitalization, and to improve the patients’ quality of life.
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